There are a number of current rheumatology-related clinical studies at Washington University.
Clinical trials, also known as research studies or patient studies, are essential in the fight against disease. They determine if new treatments are safe and effective and work better than current treatments.
Clinical studies help us find new ways to treat and learn about rheumatologic diseases. They are a vital tool in improving the quality of life for people during and after treatment.
When you take part in a rheumatology clinical study, you add to our knowledge and help improve care for future patients.
- The research team will explain all the study details, including potential benefits and risks.
- Each study is monitored to make sure it is as safe as possible, and your study records are kept private and confidential.
- Only the research team and your doctor or nurse will have access to your records.
- You can leave a study at any time for any reason.
- We have a number of rheumatology clinical studies at Washington University.
- Learn more about other clinical studies at Washington University
- The Volunteer for Health program supports patient-oriented research at Washington University. Find more information and join the Research Participant Registry.
- What is the purpose of the study?
- What do I have to do?
- How long will the study last?
- What are the risks and side effects?
- Will it cost me anything?
- Will I receive money?
- Can I withdraw at any time?
- Will the study help me now?
The principal investigator is the doctor in charge of the clinical study. He or she prepares a plan–or protocol–for the study. The protocol explains what will be done
during the trial, including:
- The reason for doing the study
- Who is eligible for the study
- How drugs or treatments will be given, what dose and how often
- What medical tests will be done and how often
- What types of information will be collected
Current Rheumatology Clinical Studies
1.Observation and Translation of Axial Spondyloarthritis:
Current Target Population: Seropositive Rheumatoid Arthritis
– Inclusion: Clinical Diagnosis of RA with +RF and/or CCP
– Exclusion: prior negative testing for HLA-B27
– Renumeration: $25 for saliva to test for HLA-B27 and if positive $50 for a blood draw
– Email: meganarb@wustl.edu
2.BMS026024 Afimetoran (daily oral), a potent/selective TLR 7and TLR8 small molecule inhibitor leading to reduced pDCs, mDSs, monocyte activation
Current Target Population: Moderately active SLE with joint and/or skin disease
– Inclusion: 18-70 yo, SLE dx 12+ weeks, ANA +, stable dose of background SOC therapy, modified SLEDAI at least 6, one BILAG A or two BILAG B body systems (one system must be mucocutaneous or MSK)
– Exclusion: Active severe LN, current or recent biologic use, dx of fibromyalgia if it impacts assessment of SLE, active/recent/chronic infection requiring tx significant cardiac or thrombotic hx, hx of most malignancies, marijuana use, use of high potency TOPICAL steroids
– Remuneration: $150 plus parking per visit
– Email: kncruz@wustl.edu
3. Biogen TOPAZ Litifilimab for SLE (subq Q4weeks), a humanized IgG1 mAb that recognizes BDCA2 expressed on the surface of human pDCs:
https://www.nejm.org/doi/full/10.1056/NEJMoa2118024
Current Target Population: Moderately active SLE with joint and/or skin disease
– Inclusion: SLE dx 24+ weeks, stable dose of background SOC therapy, modified SLEDAI at least 6, one BILAG A or two BILAG B body systems
– Exclusion: Active severe LN, current or recent biologic use, hx of malignancy, chronic or recurrent infections, significant cardiac hx, active skin conditions other than CLE (psoriasis, rosacea, rheumatoid nodules, drug induced lups), non-medical marijuana use
– Remuneration: $100 per visit plus parking and transportation. Reimbursement up to $77 for childcare or caregiver
– Email: kncruz@wustl.edu
4.A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Clinical Effect, Pharmacodynamic, Pharmacokinetic and Safety Profile of PF-06823859 in Adult Participants With Active CLE or SLE With Cutaneous Manifestations
https://clinicaltrials.gov/study/NCT05879718?tab=history&a=5
Current Target Population: CLE or SLE with active cutaneous manifestations NOT on scalp or face
– Inclusion: 18-75 yo, active, biopsy proven CLE or SLE with cutaneous manifestations, stable dose of background SOC therapy for 12+ weeks (either immunosuppressant or antimalarials + corticosteroids , CLASI-A score of 8+
– Exclusion: Active severe LN or CNS lupus, current or recent biologic use, other skin conditions that may confound disease assessment, active/recent/chronic infection requiring tx, significant cardiac or thrombotic hx, hx of most malignancies, vaping or e-cigarette use, use of high potency TOPICAL steroids
– Remuneration: ~$100 plus parking per visit
– Email: kncruz@wustl.edu
5. A randomized, double-blind, placebo-controlled multicenter phase 3 study to evaluate efficacy, safety and tolerability of ianalumab on top of standard-of-care therapy in patients with systemic lupus erythematosus (SIRIUS-SLE 2)
https://clinicaltrials.gov/study/NCT05624749
Current Target Population: Moderately active SLE with joint and/or skin disease
– Inclusion: 12+ years old, SLE dx for at least 6 months, ANA+, stable dose of background SOC therapy for 12+ weeks, SLEDAI score at least 6, one BILAG A or two BILAG B systems
– Exclusion: Active severe lupus kidney disease, current or recent biologic of JAKi use, active/recent/chronic infection requiring tx, hx of most malignancies w/in 5 years
– Remuneration: $76 plus parking per visit
-Email: kncruz@wustl.edu
6. A Multicenter Randomized Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Anifrolumab in Adult Patients with Active Proliferative Lupus Nephritis
https://www.astrazenecaclinicaltrials.com/study/D3466C00001
Current Target Population: Active proliferative class III or IV LN (concomitant class V allowed)
– Inclusion: 18-70 years old, updated 2019 SLE criteria dx, renal biopsy proven active proliferative LN (w/in 6 months or during screening) requiring high dose CS and immunosuppressive therapy, eGFR ≥ 35 mL/min/1.73 m2, UPCR > 1 mg/mg
– Exclusion: Pure class V LN, evidence of malignancy or current infection, hx of dialysis w/in 12 months or anticipated need within 6 months, hx of recurrent infection w/in 52 weeks, previous anifrolumab tx, biologic tx w/in 5 half lives, current or recent JAKi or BTKi tx, receipt of certain txs for current LN flare (contact Katrina for more details)
– Remuneration: $100 plus parking per visit
-Email: kncruz@wustl.edu
Clinical study informational resources
There are clinical studies throughout the United States. Find more information about general clinical studies at the following resources:
- American College of Rheumatology Clinical Trials information in English and in Spanish
- View the National Institute of Health (NIH) listing of clinical trials throughout the world
- Visit the NIH general information page or check out the find a study tool
- The Lupus Foundation of America has a clinical trial matching online tool
- The Arthritis Foundation also has a trial finder tool
For more information and whether or not you qualify for a study, email Katrina Peterson